Regenxbio
(NASDAQ) RGNX
Regenxbio Financials at a Glance
Market Cap
$809.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$87.82M
Net Income (TTM)
-$290.01M
EPS (TTM)
-$5.59
P/E Ratio
-2.80
Dividend
$0.00
Beta (Volatility)
1.50 (Average)
Dividend
$0.00
Beta (Volatility)
1.50 (Average)
Price
$15.68
Volume
1,831
Open
$15.37
Price
$15.68
Volume
1,831
Open
$15.37
Previous Close
$15.65
Daily Range
$14.92 - $15.75
52-Week Range
$5.46 - $16.19
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.50 (Average)
Price
$15.68
Volume
1,831
Open
$15.37
Previous Close
$15.65
Daily Range
$14.92 - $15.75
52-Week Range
$5.46 - $16.19
Estimated Earnings Date
Aug 6, 2026
RGNX News
Why Regenxbio Stock Is Way Up Today
RGNX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Regenxbio
Industry
Biotechnology
Sector
Health CareEmployees
371
CEO
Curran M. Simpson
Website
www.regenxbio.comHeadquarters
Rockville, MD 20850, US
RGNX Financials
Key Financial Metrics (TTM)
Gross Margin
-0.14%
Operating Margin
-292.28%
Net Income Margin
-330.23%
Return on Equity
-232.50%
Return on Capital
-44.38%
Return on Assets
-84.83%
Earnings Yield
-35.71%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$809.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
51.70M
Volume
1.83K
Avg. Volume
1.89M
Financials (TTM)
Gross Profit
-$120.00K
Operating Income
-$256.69M
EBITDA
-$229.35M
Operating Cash Flow
-$233.78M
Capital Expenditure
-$2.63M
Free Cash Flow
-$236.40M
Cash & ST Invst.
$150.49M
Total Debt
$71.07M
Regenxbio Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$6.39M
-92.8%
Gross Profit
-$4.68M
-105.5%
Gross Margin
-73.22%
N/A
Market Cap
$809.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$2.29M
N/A
Employees
353
N/A
Net Income
-$90.05M
-1580.4%
EBITDA
-$77.49M
-516.4%
Quarterly Fundamentals
Total Cash
$150.49M
-43.8%
Total Debt
$71.07M
-11.0%
Accounts Receivable
$10.94M
-42.9%
Inventory
$0.00
N/A
Long Term Debt
$63.20M
-12.1%
Short Term Debt
$7.87M
-0.9%
Return on Assets
-84.83%
N/A
Return on Invested Capital
-94.79%
N/A
Free Cash Flow
-$77.42M
-337.5%
Operating Cash Flow
-$76.19M
-326.5%